Filter By Category
Archives
Share on -
ANIFROLUMAB
Generic Name: ANIFROLUMAB
ABSTRACT -
Anifrolumab is a human IgG1-kappa monoclonal antibody that binds subunit 1 of the type I interferon receptor and blocks type I interferon signaling. It is approved in multiple regions as add-on therapy for adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy, excluding severe active lupus nephritis or severe active central nervous system lupus in many labels.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- The approved adult regimen is 300 mg by intravenous infusion every 4 weeks where the product is authorized.
- Administer over the label-recommended infusion time with monitoring for infusion reactions.
- Use in combination with standard lupus therapy according to specialist guidance.
SIDE EFFECTS–
- Possible side effects include:
- Upper respiratory tract infection
- Bronchitis
- Herpes zoster
- Cough
- Infusion-related reactions
- Headache
- Nausea
- Fatigue
- Hypersensitivity reactions
ALLRGIC REACTIONS–
- Possible allergic reaction symptoms include:
- Rash
- Urticaria
- Angioedema
- Bronchospasm
- Anaphylaxis symptoms
- Important: Patients who develop an allergic reaction to Anifrolumab should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
- Live or live-attenuated vaccines should be avoided during treatment.
- Other biologic immunosuppressants may increase infection risk.
- Immunosuppressive corticosteroids or antimetabolites can add to infection risk.
- Therapy may need to be interrupted for serious infection.
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Screen for active infection before initiating therapy.
- Monitor for herpes zoster and other infections.
- Not recommended for severe active lupus nephritis or severe active CNS lupus unless a specialist determines otherwise.
- Assess vaccination status before treatment when possible.
WARNINGS –
- Serious infections and hypersensitivity reactions can occur.
- Seek urgent care for breathing difficulty, facial swelling, fever, shingles-like rash, or severe infusion reaction.
- Use only under specialist supervision.
- Keep out of reach of children.
Share on -
. Developed by